See more here:
Cerevance Presents Positive Results from Phase 1 Study of CVN293 at American Academy of Neurology 2025 Annual Meeting
Related Post
- INVO Fertility Confirms New Nasdaq Trading Symbol of “IVF” - April 25th, 2025
- Alkeus Pharmaceuticals Announces Presentations of Gildeuretinol Data During the Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting May... - April 25th, 2025
- Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference - April 25th, 2025
- Guerbet: Q1 2025 revenue - April 25th, 2025
- PCI Biotech Holding ASA: Annual Report 2024 - April 25th, 2025
- Vivoryon Therapeutics N.V. Signs Financing Agreement for up to EUR 15 Million - April 25th, 2025
- Faraday Pharmaceuticals to Host Satellite Symposium at SCAI 2025 on Exploring New Frontiers in Reducing Ischemia-Reperfusion Injury - April 25th, 2025
- Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm... - April 25th, 2025
- Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025 - April 25th, 2025
- Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025 - April 25th, 2025
- Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological... - April 25th, 2025
- FluidForm Bio™ Announces Advance in Bioprinted Tissue Therapies with Landmark Publication in Science Advances - April 25th, 2025
- PROCEPT BioRobotics' Aquablation Therapy Spotlighted at 2025 AUA Annual Meeting Along with Expert-Led Workshops - April 25th, 2025
- Cytek Biosciences to Report First Quarter 2025 Financial Results on May 8, 2025 - April 25th, 2025
- Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO) - April 25th, 2025
- Seer to Report First Quarter 2025 Financial Results on May 13, 2025 - April 25th, 2025
- NurExone to Showcase Breakthrough in Facial Nerve Regeneration at ISEV 2025 - April 25th, 2025
- GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update - April 25th, 2025
- Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 - April 25th, 2025
- Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May - April 25th, 2025
- Oncotelic CEO Vuong Trieu to Present Innovative "Deciparticles" Platform at IDDST-Europe 2025 Conference in Stockholm - April 23rd, 2025
- Andrew Taylor joins Novonesis’ Executive Leadership Team - April 23rd, 2025
- Elite Clinical Network and HealthyU Clinics Announce Strategic Partnership to Expand Access to Clinical Research - April 23rd, 2025
- Digicann Ventures Provides Update Regarding Proposed RTO Transaction - April 23rd, 2025
- Sirona Biochem Announces Debenture Financing - April 23rd, 2025
- Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors - April 23rd, 2025
- Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones - April 23rd, 2025
- Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe... - April 23rd, 2025
- Longeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025 - April 23rd, 2025
- UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates - April 23rd, 2025
- NurExone Appoints Biotech Industry Leader - Jacob Licht to Lead U.S. Operations and Exo-Top Manufacturing Expansion and Completes Continuance into... - April 23rd, 2025
- OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs), GlycOBI® and... - April 23rd, 2025
- Roche receives CE Mark for its Chest Pain Triage algorithm to enhance detection of Acute Coronary Syndrome (ACS) - April 23rd, 2025
- VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a... - April 23rd, 2025
- Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025 - April 23rd, 2025
- Cytovation Raises US$6m to Advance Phase 2 Development of CY-101 in Adrenocortical Carcinoma to First Clinical Readouts - April 23rd, 2025
- Antag Therapeutics expands senior team to support clinical progress - April 23rd, 2025
- Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS - April 23rd, 2025
- Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers - April 23rd, 2025
- Orion Group Interim Report January–March 2025 - April 23rd, 2025
- Precision Neuroscience Receives FDA Clearance for High-Resolution Cortical Electrode Array - April 19th, 2025
- Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite’s Namodenoson, Leading U.S. Medical Centers Seek Authorization for... - April 19th, 2025
- Psyence Group Announces Share Consolidation - April 19th, 2025
- BVI Medical Announces Approval of Breakthrough Technology: FDA 510(k) Clearance of its Laser Endoscopy Ophthalmic System: Leos™ - April 19th, 2025
- Actum Pharma Expands Executive Team to Launch Enhanced Services Program to Support Biopharma Product Commercialization and Market Success - April 19th, 2025
- Best Testosterone Booster Supplements For Muscle Gain & Increase Testosterone For Men Over 40 Or 50 Over The Counter Pills By (Testo Prime) - April 19th, 2025
- Best Testosterone Boosters for Men Over 40 and 50: TestoPrime Under Review - April 19th, 2025
- Best Testosterone Booster Supplements Canada: TestoPrime for Males Over 40 and 50 (By TestoPrime CA) - April 19th, 2025
- Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility - April 19th, 2025
- TELA Bio to Announce First Quarter 2025 Financial Results - April 19th, 2025
- NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors - April 19th, 2025
- Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC - April 19th, 2025
- Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 19th, 2025
- Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025 - April 19th, 2025
- Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers - April 19th, 2025
- Dipharma Awarded Bronze Medal by Ecovadis for Sustainability - April 19th, 2025
- Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria - April 19th, 2025
- Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU) - April 19th, 2025
- Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application - April 19th, 2025
- 23andMe Provides Update Regarding Court-Supervised Sale Process - April 19th, 2025
- Longevity Health Holdings Announces Execution of Merger Agreement With 20/20 Biolabs - April 15th, 2025
- Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing - April 15th, 2025
- UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 - April 15th, 2025
- Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships - April 15th, 2025
- Verano Announces Promotion and Appointment of Richard Tarapchak as Chief Financial Officer - April 15th, 2025
- VIVUS Announces Enrollment of First Patient in Phase 2 Clinical Trial Assessing Ethanol-Free Carmustine as a Component of High-Dose Chemotherapy Prior... - April 15th, 2025
- [Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US - April 15th, 2025
- Prostadine Drops Reviews [We Tested It] Read Ingredients, Side Effects for Urinary System - April 15th, 2025
- Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country - April 15th, 2025
- Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics - April 15th, 2025
- Ipsen - March 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital - April 15th, 2025
- AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell disease - April 15th, 2025
- Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering... - April 15th, 2025
- Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 15th, 2025
- Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases - April 15th, 2025
- Cue Biopharma to Host Business Update Call and Webcast - April 15th, 2025
- BioSyent to Attend Planet MicroCap Showcase - April 15th, 2025
- Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financial Results - April 15th, 2025
- MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025 - April 15th, 2025
- NAYA Biosciences Announces Strategic Decision to Separate Fertility and Oncology Businesses into Distinct Operations – Company Renamed “INVO... - April 15th, 2025
Recent Comments